Deutsche Bank Predicts 250% Gain for Psychedelic Drug Developer AtaiBeckley

• Deutsche Bank initiated coverage on AtaiBeckley with a buy rating and a $12 price target, indicating a potential 250% gain.
• AtaiBeckley is positioned as a leader in the "Psychedelic Renaissance" for mental health treatments.
• The company is developing BPL-003 and VLS-01 for treatment-resistant depression, with potential peak sales of $4 billion and $2 billion respectively.
• EMP-01, an oral MDMA derivative for seasonal affective disorder, could reach $1 billion in peak sales.
• The FDA's stance on psychedelic therapies has eased, with expected rescheduling of approved drugs from Schedule I to more accessible categories.